Trial ID:
IRB-26-8741
Marin Xavier, MD

Inclusion Criteria

Patients must:

  • be 18 years of age or older
  • have a confirmed diagnosis of CLL/SLL
  • have had prior exposure to a covalent BTK inhibitor (cBTKi), a non-covalent BTK inhibitor (ncBTKi), and a B-cell lymphoma-2 inhibitor (BCL-2i)
  • agree to use highly effective contraception throughout the duration of the study for women of childbearing potential (WOCBP) and males with WOCBP partners

Exclusion Criteria

Patients must not:

  • have known or suspected prolymphocytic leukemia or Ricther's transformation
  • have been previously treated with a BTK degrader
  • have a history of a bleeding disorder

Additional Info

Study visits for enrolled patients are every two weeks and will include a physical exam and lab assessments. All physician visits will take place at Prebys Cancer Center.

For more information, search NCT07221500 on https://clinicaltrials.gov

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org